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A B S T R A C T
Purpose
This phase III randomized open-label clinical trial was designed to evaluate the efficacy and safety
of the steroidal aromatase inactivator exemestane versus the antiestrogen tamoxifen as first-line
treatment for metastatic breast cancer (MBC) in postmenopausal women.
Patients and Methods
The study was conducted at 81 centers and enrolled postmenopausal patients with measurable
hormone-sensitive metastatic or locally advanced breast cancer. Prior adjuvant chemotherapy
and/or tamoxifen were allowed. One previous chemotherapy regimen and no prior hormone
therapy for advanced disease were permitted. Patients were randomly assigned to receive
exemestane 25 mg or tamoxifen 20 mg orally once daily until disease progression or unacceptable
toxicity occurred.
Results
A total of 371 patients enrolled at 79 sites (182 exemestane, 189 tamoxifen) were included in the
analysis. Both treatments were generally well tolerated without major toxicity. Overall response
rate was greater for exemestane than for tamoxifen treatment (46% v 31%; odds ratio  1.85;
95% CI, 1.21 to 2.82; P  .005). Median progression-free survival (PFS) was longer with
exemestane (9.9 months; 95% CI, 8.7 to 11.8 months) than with tamoxifen (5.8 months; 95% CI,
5.3 to 8.1 months). However, these early differences (Wilcoxon P  .028) did not translate to a
longer-term benefit in PFS, the primary study end point (log-rank P  .121). There was also no
difference in survival between both study arms.
Conclusion
Exemestane is an effective and well-tolerated first-line hormonal treatment for postmenopausal
women with MBC and offers significant early improvement in time to tumor progression when
compared with tamoxifen.
J Clin Oncol 26:4883-4890. © 2008 by American Society of Clinical Oncology
INTRODUCTION
Tamoxifen, a competitive estrogen-receptor (ER)
antagonist, was until recently the standard first-
line hormonal therapy for metastatic hormone-
receptor–positive breast cancer (MBC) in
postmenopausal women.1 The development of re-
sistance to tamoxifen, and long-term toxicities in-
cluding thromboembolic events and endometrial
cancer, has led to increasing use of alternative hor-
monal therapies including exemestane (Aromasin;
Pfizer Inc, New York, NY), a steroidal aromatase
inactivator, and other aromatase inhibitors (AIs).
AIs inhibit the conversion of androgens into
estrogens, thereby significantly reducing circulating
estrogens in postmenopausal women. Their efficacy
in breast cancer is well established.2 Currently avail-
able AIs include the steroidal compound exemes-
tane as well as nonsteroidal compounds such as
anastrozole and letrozole.3-5 Exemestane has been
extensively investigated across the spectrum of
hormone-receptor-positive postmenopausal breast
cancer. Phase II studies have demonstrated its effec-
tiveness as third-line therapy for breast cancer pro-
gressing after tamoxifen and nonsteroidal AIs.4,6,7
Exemestanewasalso superior tomegestrol acetate in
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prolonging time to progression and even overall survival in patients
who had progressed with tamoxifen.8
The European Organisation for the Research and Treatment of
Cancer (EORTC) Breast Cancer Cooperative Group has investigated
the efficacy and tolerability of exemestane compared with tamoxifen
in first-line for hormone-responsive MBC in postmenopausal
women.Thephase IIportionof the trialwasdesigned toassess efficacy
and safety of exemestane, with the intent to extend the trial into a
randomized phase III in the event of promising results.9 Additional
safety studies focusing on lipids and endometriumwere conducted in
parallel.10,11 Of 62 patients who received exemestane, 41% (95% CI,
29% to 53%) achieved an objective complete or partial response,
whereas the remission rate for 60 tamoxifen-treated patients was 17%
(95% CI, 7% to 27%).9 A low incidence of clinically relevant toxicity
was observed, and the criteria for extension into a phase III random-
ized trial were met.
The phase III study reported herein was specifically designed to
compare the efficacy and safety of first-line therapy with exemestane
versus tamoxifen in postmenopausal womenwith hormone-sensitive
MBC, focusing on progression-free survival (PFS) as the primary
study end point.
PATIENTS AND METHODS
Study Design
This was a multicenter, randomized open-label phase II/III study con-
ducted at 81 centers. All phase II data were incorporated into this report.
Eligible patients were randomly assigned to receive either exemestane (25mg)
or tamoxifen (20mg)orally oncedaily.Central randomizationwasperformed
at the EORTC Data Center in a 1:1 ratio, using the minimization method12
based on stratification for institution, previous adjuvant tamoxifen (yes v no),
previous chemotherapy for metastatic disease (yes v no), and dominant met-
astatic site (visceral others v bone only v bone and soft tissue v soft tissue
only). Patients received the designated treatment until disease progression or
occurrence of unacceptable toxicity. The study was conducted in accordance
with the Declaration of Helsinki, and the protocol was approved by all local
ethics boards.
Patients
Eligibility criteria were similar to those of the phase II part of the trial.9
Patients had to provide written informed consent before study participation.
Female patients with metastatic or locally recurrent inoperable breast cancer
with at least one bidimensionally measurable lesion were eligible, provided
that they were postmenopausal, either by natural installation or after surgical
castration. Patients with radiotherapy- or chemotherapy-induced amenor-
rhea lasting at least 1 year also were eligible, but for them and for any patient
younger thanage56years, follicle-stimulatinghormone, luteinizinghormone,
and plasma estradiol had to be within the postmenopausal range. Target
lesions had to bemeasurable in two perpendicular diameters, with at least one
diameterof at least 2.5 cmandnotpreirradiated.Exceptions included liver and
extra-abdominal lesions that were followed by computed axial tomography
(CT) of at least 2.0 cm; lesions followed by chest x-ray of at least 1.5 cm;
photographed skin lesions of at least 1 cm; and purely lytic bone lesions
identified by x-ray or CT scan, surrounded by calcified bone, at least 1 cm in
diameter, and not previously irradiated unless they had clearly progressed
since and the irradiation had occurred at least 3 months before. Primary
tumors or metastases had to be hormone-receptor positive. Patients with
hormone-receptor–unknown tumors were also eligible, provided that they
had a disease-free interval (DFI) of at least 2 years since completing adjuvant
therapy (or after surgery without adjuvant therapy). Prior adjuvant chemo-
therapy and/or tamoxifen were allowed, but the recurrence-free interval after
tamoxifenhad tobe at least 6months.Noprevioushormone therapy forMBC
was allowed; previous radiotherapy and at most one previous chemotherapy
regimen for metastatic disease were permitted, provided that the patient had
recovered completely fromtreatment-associated acute toxicities. Patientswith
rapidly progressive disease, large-volume visceral disease, or brain metastases
were excluded.
Treatment Protocol and Evaluations
Patients were instructed to take either exemestane or tamoxifen orally
once daily after breakfast until disease progression or unacceptable toxicity.
Patients were evaluated at baseline; at weeks 8, 16, and 24; then every 12weeks
until week 96; and thereafter every 24 weeks. Baseline assessments included a
detailed history of previous treatments. A complete physical examination and
laboratory evaluations were performed at baseline and at each follow-up visit.
Patients randomly assigned
(N = 382)
Tamoxifen
(n = 192)
Exemestane
(n = 190)
ITT Population (n = 189)(n = 182)
PP Population (n = 176)(n = 164)
Excluded from analysis because of
inadequate data documentation (n = 3)
Did not complete per protocol, n (%): 17 (10)*
Did not have measurable disease: 6 (3)
Did not have documented MBC: 3 (2)
Major protocol violations: 8 (4)
Did not complete per protocol, n (%): 13 (6)*
Did not have measurable disease: 2 (1)
Did not have documented MBC: 1 (< 1)
Major protocol violations: 8 (4)
ER- and PgR- negative: 1 (< 1)
Treatment initiated before 
  random assignment: 1 (< 1)
Excluded from analysis because of
inadequate data documentation (n = 8)
Fig 1. Patient flow. ER, estrogen receptor;
PgR, progesterone receptor; ITT, intention
to treat; MBC, metastatic breast cancer; PP,
per protocol. (*) Patients may have had
more than 1 reason for discontinuation.
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Adverse events (AEs) were graded according to National Cancer Institute of
Canada Common Toxicity Criteria (NCIC-CTC; December 1994 version)
definitions.Tumorassessments at baseline comprised chest radiographs, bone
scintigraphy, and imaging of target lesions. Tumor evaluations were made at
8-week intervals, using the same methods as at baseline. If the number of
measurable lesions was too great, then up to eight representative lesions were
selected. Tumor responses were classified using WHO criteria.13 During the
phase II part of the study, an independent panel of radiologists reviewed all
objective responses. During the phase III trial, which focused on PFS, all case
report forms were reviewed at the EORTC Data Center and by the study
coordinator (R.J.P.) or the EORTC director (P.T.).
Study End Points
The primary efficacy end point for the phase III trial was PFS, defined as
the length of time between random assignment and the onset of disease
progressionordeath.Whenprogressive disease (PD)was established, the time
to progression was the time from random assignment until the day on which
progression was suspected and documented. Progressive disease was defined
as an increase of at least 25% in the size of at least one bidimensionally or
unidimensionally measurable lesion or as the appearance of any new lesion.
Appearance of pleural effusion or ascites with positive cytology were also
considered tobePD.Pathologic fracturesorbonecollapsewerenotnecessarily
indicative of PD. The development of brain metastases was considered as PD
even if disease elsewhere responded.
Secondary end points were overall survival (number of deaths at final
analysis) and safety. Themajor safety end pointwas the incidence and severity
of AEs based on NCIC-CTC grades.
Statistical Considerations
A hazard ratio (HR) of 0.71 in favor of exemestane was hypothesized
based on earlier phase III trial data and the assumption that the median PFS
would be 7.14monthswith tamoxifen and 10.0monthswith exemestane.14-16
The study was designed to detect a 0.71 HR for PFS with 80% power by a
two-sided log-rank test (  5%). To obtain this power, 278 events were
required; therefore, based on the anticipatedmedianPFS, 342 patientswere to
be enrolled. Data from the phase II and phase III portions of the trial were
pooled for analysis.
All statistical analyses were based on the intention-to-treat (ITT) popu-
lation. TheKaplan-Meiermethodwas used to calculate PFS from the random
assignment date until documented PD or death. Statistical testing was per-
formed by log-rank test; associated HR values smaller than 1 are in favor of
exemestane. Similar statistical methods were used for overall survival. An
additional comparison of PFS was performed post hoc using the Wilcoxon
test. Response rates were compared by 2 test and associated odds ratios.
Table 1. Baseline Characteristics
Characteristic
Treatment
All Patients (N  371)Exemestane (n  182) Tamoxifen (n  189)
No. % No. % No. %
Age, years
Median 63 62 63
Range 37-86 37-87 37-87
Disease-free interval, months
Median 46 47 46
Range 0-378 0-491 0-491
WHO performance status
0 84 46.2 80 42.3 164 44.2
1 79 43.4 84 44.4 163 43.9
2 19 10.4 25 13.2 44 11.9
Dominant metastatic site
Visceral 87 47.8 88 46.6 175 47.2
Bone only 21 11.5 22 11.6 43 11.6
Bone  soft tissue 43 23.6 45 23.8 88 23.7
Soft tissue 31 17.0 34 18.0 65 17.5
ER/PgR status
ER/PgR 104 57.1 106 56.1 210 56.6
ER/PgR 42 23.1 52 27.5 94 25.3
ER/PgR unknown 14 7.7 11 5.8 25 6.7
ER–/PgR 8 4.4 9 4.8 17 4.6
ER–/PgR 0 0.0 1 0.5 1 0.3
Both unknown 14 7.7 10 5.3 24 6.5
Prior treatments
Prior radiotherapy 75 41.2 79 41.8 154 41.5
Previous systemic therapy 76 41.7 79 41.8 154 41.5
Chemotherapy only 38 20.9 38 20.1 76 20.5
Hormone therapy only 21 11.5 16 8.5 36 9.7
Both chemotherapy and hormone therapy 17 9.3 25 13.2 42 11.3
Previous chemotherapy 55 30.2 63 33.3 118 31.8
Adjuvant treatment only 44 24.2 51 27.0 95 25.6
Metastatic disease only 8 4.4 8 4.2 16 4.3
Both adjuvant and metastatic 3 1.6 4 2.1 7 1.9
Previous adjuvant tamoxifen 38 20.9 39 20.6 77 20.8
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor.
Exemestane in First-Line Advanced Breast Cancer
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Values greater than 1 reflect better odds for response to exemestane. A Cox
proportional hazards model was used as an exploratory analysis, with back-
ward and forward selection, while stratifying for treatment, to select a prog-
nostic model.
The 5% levelwas used as cutoff for statistical significance throughout the
study includingexploratoryanalyses.Patientswhodidnot experienceanevent
(progression and/or death) by the time of analysis were censored at the last
available follow-up date. Analyses of AEs were descriptive and were summa-
rized as the worst grade of toxicity per patient.
RESULTS
Patients
Between October 1996 and December 2002, 382 patients were
randomly assigned to receive exemestane (n  190) or tamoxifen
(n 192). Two sites, which enrolled 11 patients, were excluded from
analysis because of inadequate documentation, leaving 79 sites with
371 assessable patients (182 exemestane, 189 tamoxifen), who were
analyzedonan ITTbasis. Theflowofparticipants through the study is
summarized in Figure 1.
Baseline characteristics of the ITT population are depicted in
Table 1. Demographics were similar in both treatment groups. Most
of the tumors (93%) were ER and/or progesterone-receptor positive.
Most patients (73%) had two or more involved metastatic sites. In
each treatmentarm,an identicalproportionofpatients (58%)hadnot
previously received any systemic treatment.
Patient datawere collected throughMay 12, 2004,with amedian
follow-up of 29 months (interquartile range, 20 to 53 months). The
median treatment duration was 6.57 months for tamoxifen (95%CI,
5.78 to 10.91 months) and 11.50 months for exemestane (95% CI,
10.18 to 13.54 months). In the exemestane- and tamoxifen-treated
groups, 159 (87.4%) and 168 (88.9%) patients discontinued treat-
ment, respectively.Theprincipal reasonfordiscontinuationwasPDin
136 patients (74.7%) receiving exemestane and 138 (73%) receiving
tamoxifen. The remaining patients who discontinued did so for rea-
sons other than PD, but only one patient with exemestane and two
patients with tamoxifen stopped treatment because of toxicity.
Forty-four patients remain without confirmation of treatment dis-
continuation, and their data were censored at their last known
treatment date.
Efficacy Analyses
PFS. Atotal of 319 events (progressionordeath)wereobserved:
161 (85%) in the tamoxifen arm and 158 (87%) in the exemestane
arm. The associated HR was 0.84 (95% CI, 0.67 to 1.05) in favor of
exemestane. The HR for the 79% of patients without prior hormonal
treatment was 0.83 in favor of exemestane. In addition, at both 6 and
12months, thepercentageof patientswithoutdisease progressionwas
greaterwith exemestane (66.2%[95%CI, 59.3%to73.1%]and41.7%
[95%CI, 34.5% to 48.9%], respectively) than with tamoxifen (49.5%
[95% CI, 42.2% to 56.6%] and 31.2% [95% CI, 24.4% to 37.9%]).
Although results of the log-rank test analysis were not statistically
significant (P  .121), observation of the Kaplan-Meier curves (Fig
2A) indicated that the HR was not constant over time, with appar-
ently greater differences in the earlier part of the follow-up period.
Indeed, the 4.1-month difference in median PFS between treatment
arms (Table 2) was statistically significant using the Wilcoxon test
(P .028), which gives greater weight to earlier events. In a follow-up
analysis of key endpoints after amedianof 46months, theHR forPFS
was similar at 0.87 (95%CI, 0.70 to 1.08).
Weundertook exploratory analyses of PFSbypotential prognos-
tic factors. Regardless of treatment, patients with only one involved
site (P .0001) and those older than 65 years (P .014) had a longer
PFS. Dominant metastatic site, double-receptor phenotype, previous
chemotherapy, previous hormonal therapy, DFI, performance status,
and bodymass index did not have prognostic value.
Finally, the results of sensitivity analyses including the 11patients
excluded because of inadequate documentation did not differ from
those reported for the 371 assessable patients (data not shown).
Overall survival. As shown in Table 2 and illustrated in Figure
2B,nodifferences inoverall survivalwereobservedbetween treatment
arms (log-rank P .821). The 1-year survival rates in the tamoxifen
and the exemestane groups were 82% and 86%, respectively. TheHR
for overall survival was 1.04 (95% CI, 0.76 to 1.41) after 29 months
follow-up. At the 49-month updated analysis, 163 patients had died,
81 in the tamoxifen arm and 82 in the exemestane arm, and the HR
remained essentially the same (HR 1.13; 95%CI, 0.85 to 1.50).
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Fig 2. (A) Progression-free and (B) overall survival. O, total number of events
observed; N, total number of patients.
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Tumor Response and Prognostic Factors
As shown in Table 2, the objective response rate (complete re-
sponse  partial response) was 46% for exemestane and 31% for
tamoxifen. Consistent with the higher response rate in favor of ex-
emestane (odds ratio 1.85; 95%CI, 1.21 to 2.82; exact2 P .005),
there were fewer patients with disease progression at 29-month
follow-upwithexemestane (33patients [18.1%]) thanwith tamoxifen
(54 patients [28.6%]).
Response rates by prognostic factors and treatment arm are
shown in Table 3.With the exception of patients who received previ-
ous adjuvant tamoxifen, inwhomresponse rateswere nearly identical
for both study arms, response rates for exemestane-treated patients
were higher than for tamoxifen-treated patients in each prognos-
tic subgroup.
Safety
Both treatmentswere generallywell tolerated, andno treatment-
relateddeathswere reported.The incidenceofAEs is shown inTable 4
as the worst grade recorded per patient. In total, 61 grade 3/4 nonhe-
matologic AEs were observed with tamoxifen versus 41 with exemes-
tane, and21grade3/4 events related to laboratory testing (hematology
or chemistry) were recorded with tamoxifen versus 30 with exemes-
tane. Serious AEs were infrequent, and a causal relationship with
Table 2. Efficacy Results
Result
Exemestane (n  182) Tamoxifen (n  189)
No. % No. %
PFS events 158 87 161 85
Median PFS, months 9.9 5.8
95% CI 8.7 to 11.8 5.3 to 8.1
PFS at 6 months 66.2 49.4
95% CI 59.3 to 73.1 42.2 to 56.6
PFS at 12 months 41.7 31.2
95% CI 34.5 to 48.9 24.24 to 37.9
OS events 82 45 81 43
Median OS, months 37.2 43.3
95% CI 29.2 to 45.5 32.8 to 51.6
OS at 12 months 86.4 82.0
95% CI 81.3 to 91.5 76.4 to 87.6
Complete response 15 8.2 6 3.2
Partial response 68 37.4 53 28.0
No change 54 29.7 67 35.4
Progressive disease 33 18.1 54 28.6
Early death/malignant disease 0 0.0 1 0.5
Early death/other 3 1.6 1 0.5
Not assessable 9 4.9 7 3.7
Abbreviation: OS, overall survival; PFS, progression-free survival.
Table 3. Response Rates by Prognostic Factors
Prognostic Factor
Exemestane (n  182) Tamoxifen (n  189)
No. of Responses No. of Patients % No. of Responses No. of Patients %
Dominant site
Visceral 38 87 44 27 88 31
Bone only 10 21 48 3 22 14
Bone and soft tissue 18 43 42 16 45 36
Soft tissue only 17 31 55 13 34 38
Receptor status
ER and PgR 51 104 49 43 106 41
ER or PgR 22 50 44 13 61 21
Previous therapy
None 52 106 49 35 110 32
Hormonal (adjuvant tamoxifen) 7 21 33 6 16 38
Chemotherapy 17 38 45 14 38 37
Hormonal and chemotherapy 7 17 41 4 25 16
Abbreviations: ER, estrogen receptor; PgR, progesterone receptor.
Exemestane in First-Line Advanced Breast Cancer
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treatment was rarely established. Patients in both arms of the study
experienced symptoms related to estrogen suppression; however,
most of these weremild tomoderate in severity. Patients treated with
exemestane had fewer complaints of grade 2/3 hot flashes (6.5% v
12.2%) but more grade 1/2 arthralgia/myalgia, more cardiac dys-
rhythmia and cardiac dysfunction, and more grade 1 diarrhea.
Tamoxifen-treated patients reported vaginal discharge ormild bleed-
ing more frequently, and also more grade 2 edema. There was no
obvious trend for weight change in either group. The incidence of
phlebitis anddeep vein thrombosiswas low: one patientwith exemes-
tane had pulmonary embolism that was deemed to be disease related.
DISCUSSION
This phase III study compared exemestane and tamoxifen as first-line
therapy forpostmenopausalwomenwithMBC.ThemedianPFSwith
exemestane was 9.9 months (95% CI, 8.7 to 11.8 months) compared
with 5.8 months (95% CI, 5.3 to 8.1 months) with tamoxifen. The
log-rank test did not show a statistically significant difference between
the two PFS curves, and the Kaplan-Meier analysis (Fig 2A) indicated
that the HR was not constant over time. The Wilcoxon test, more
sensitive to earlier events and thus more clinically meaningful in a
population of MBC patients with relatively short anticipated survival
times, showed that the 4.1-month difference in PFS between treat-
ment arms was significant (P  .028). This finding is in agreement
with the significantly higher response rate observed with exemestane
than with tamoxifen (46% v 31%). Response rates by potential prog-
nostic factors remained consistently higher in the exemestane armbut
did not differ significantly by prognostic factor. No differences be-
tween the armswere detected in overall survival. Although both treat-
ments were well tolerated, patients receiving exemestane reported
more grade 1/2 arthralgia/myalgia and cardiac-related AEs, whereas
those receiving tamoxifen reported more vaginal discharge, mild
bleeding, and grade 2 edema.
It is noteworthy that the improvement in medians was met as
hypothesized. Corresponding to thesemedians, most patients had an
event (progressionordeath)within thefirst year. Interpretationof the
Kaplan-Meier curves should concentrate on the first 2 years after
random assignment because by that time point almost all patients
have either experienced progression or died.
Our results are consistent with those observed in other random-
ized phase III studies that compared AIs and tamoxifen as first-line
therapy for MBC (Table 5).14,15,17 In contrast to these previously
reported trials, patients enrolled onto our studywere required to have
measurable disease. The difference in PFS found here in favor of
exemestane is corroborated by a significantly better quality of re-
sponse and did not emanate from any subgroup analysis. These find-
ings in the metastatic setting support the growing body of evidence
that AIs have broad utility throughout the spectrum of breast cancer
and may have clinical advantages over tamoxifen. Exemestane dem-
onstrated excellent tolerability and safety. Because it differs fromnon-
steroidal AIs such as anastrozole and letrozole in its irreversible
inhibition of aromatase4 and its efficacy in MBC patients whose dis-
ease progressedduring treatmentwithnonsteroidalAIs,7 this expands
the options available for treating hormone-sensitive breast cancers.
The benefit of AIs has also been demonstrated in the adjuvant
setting, as suggested by results of large randomized adjuvant clin-
ical trials comparing anastrozole, letrozole, or exemestane with
tamoxifen.18-22 However, a recent meta-analysis of phase III clinical
trials comparing AIs with tamoxifen in early breast cancer reported
that cardiovascular AEs were more frequent with AIs, although the
absolute differencewas small (approximately 0.50%) and the number
needed to harmwas more than 180 patients.23 Our data demonstrat-
ing more cardiac-related AEs for exemestane-treated patients is con-
sistent with this finding.However, none of the cardiac events were life
Table 4. Adverse Event Profile by Treatment (grades 1 to 4)
Adverse Event
%
Exemestane
(n  182)
Tamoxifen
(n  189)
Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4
Nonhematologic events
Alopecia 3.8 0 1.1 0
Anorexia 10.4 0.5 9.5 1.1
Anxiety 11.0 0 7.4 0
Arthralgias 11.5 0 5.3 0
Cardiac dysrhythmia 5.4 1.6 1.6 1.1
Cardiac dysfunction 4.4 0.5 3.2 0.5
Constipation 8.2 0 12.2 0
Cough 14.8 0 15.9 0
Deep venous thrombosis 1.6 0 1.6 0.5
Depression 7.7 0.5 6.9 0.5
Diarrhea 8.8 0 2.6 0
Dyspnea 13.7 1.6 13.2 2.6
Edema 9.9 1.1 10.1 1.1
Fatigue/malaise/lethargy 35.7 1.1 35.4 1.1
Gastrointestinal 8.2 0 11.6 0.5
Genitourinary 4.9 0 5.3 0
Hot flashes 34.6 0.5 38.1 0
Hypertension 8.2 3.3 2.6 3.2
Infection 15.4 1.1 12.2 0
Insomnia 9.9 0 5.3 0
Musculoskeletal 4.9 0.5 0.5 1.1
Nausea 17.0 0 19.0 0.5
Neurologic, dizziness 11.5 0 10.1 0
Neurologic, sensory 8.8 0.5 9.5 1.1
Pain, bone 29.1 3.8 29.1 5.8
Pain, other 31.9 2.7 27.5 3.2
Phlebitis 0 0 0.5 0.5
Skin 11.0 0.5 9.5 0
Sweating 10.4 0 9.0 0
Vaginal bleeding 1.1 0 3.2 0.5
Vaginal discharge 2.2 0 6.9 0
Vomiting 8.2 0 6.9 0
Weight loss 16.5 0.5 14.8 1.1
Weight gain 17.6 1.1 12.2 0.5
Hematologic events
Leukopenia 17.6 0 18.0 0
Neutropenia 9.9 1.1 13.8 0
Thrombocytopenia 4.4 1.6 11.6 0.5
Anemia 28.0 1.1 34.9 1.1
Biochemical changes
Creatinine 7.1 1.6 4.2 0
Bilirubin 11.5 3.3 1.1 1.6
AST 49.5 4.9 50.8 4.8
ALT 56.6 7.7 46.0 4.2
Values missing for less than 10% of patients.
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threatening in our trial, and a distinction cannot be accurately made
between trueAI-related cardiotoxicity andpure chanceofoccurrence.
It has also been hypothesized that the higher AI-related cardiotoxicity
in some adjuvant trials was actually a reflection of a cardioprotective
effect of tamoxifen, which was not observed for patients receiv-
ing AIs.21
The expansion of hormonally based therapeutic options for all
stages of hormone-sensitive breast cancer is encouraging. Ongoing
research aimed at fully characterizing the efficacy, safety, and tolera-
bility profile of exemestane and other AIs will help elucidate which
agents are most appropriate at each stage of disease, as well as the
optimal sequence inwhich they shouldbeadministered.The results of
the present study in first-line treatment of MBC extend the positive
survival findings previously obtained comparing exemestane to
megestrol acetate in advanced disease after tamoxifen failure.8 As in
previous similar trials conducted with nonsteroidal AIs, however,
there is no survival advantage to be expected by using first-line ex-
emestane instead of tamoxifen in a palliative setting. For that reason,
lengthening of PFS isworthwhile provided that it supports the preser-
vation or improvement of quality of life. Quality of life is therefore an
important end point to include in future comparable studies of AIs as
first-line treatment of hormone-sensitiveMBC.
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